# Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age

> **NCT02919293** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd** · enrollment: 360 (estimated)

## Conditions studied

- Meningitis
- Meningococcal Meningitis
- Meningococcal Infections

## Interventions

- **BIOLOGICAL:** Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine (adjuvant-free)
- **BIOLOGICAL:** Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine(adjuvant)

## Key facts

- **NCT ID:** NCT02919293
- **Lead sponsor:** Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-08
- **Primary completion:** 2017-03
- **Final completion:** 2017-05
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2016-09-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02919293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02919293, "Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02919293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*